Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose QMF149 bronchodilation study in adults with persistent asthma
2007-002360-10Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atectura breezhaler and salmeterol + fluticasone in asthma and persistent asthma (3 arms), sponsored by Novartis. Primary endpoint: Trough FEV1. Started Sep 2007; status: completed.
02
Drugs
atectura breezhalersalmeterol + fluticasone
03
Conditions
asthmapersistent asthma
Beyond the preview
Go deeper on 2007-002360-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002360-10.